These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37550158)

  • 1. Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479].
    Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
    Eur J Med Chem; 2023 Nov; 259():115692. PubMed ID: 37550158
    [No Abstract]   [Full Text] [Related]  

  • 2. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
    Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
    Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.
    Wu Y; Zhang L; Sun Z; Qiu X; Chen Y; Su K; Yang L; Du Z; Dong Y; Yang F; Li X; Zhang X
    J Med Chem; 2023 Jul; 66(13):8545-8563. PubMed ID: 37367818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].
    Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
    Eur J Med Chem; 2016 Nov; 124():248. PubMed ID: 27592393
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy.
    Yu Z; Li Z; Yu Q; Wang Z; Song H; Sun H; Fan R; Bi A; Zhang J; Zhang X
    Chem Biol Drug Des; 2020 Feb; 95(2):270-278. PubMed ID: 31628888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
    Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
    J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
    Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
    J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia.
    Soni H
    Med Hypotheses; 2014 May; 82(5):547-50. PubMed ID: 24581673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
    Wu Y; Jiang Z; You Q; Zhang X
    Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
    Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
    Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
    Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
    Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.
    Deng G; Zhao B; Ma Y; Xu Q; Wang H; Yang L; Zhang Q; Guo TB; Zhang W; Jiao Y; Cai X; Zhang J; Liu H; Guan X; Lu H; Xiang J; Elliott JD; Lin X; Ren F
    Bioorg Med Chem; 2013 Nov; 21(21):6349-58. PubMed ID: 24055079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury.
    Fang Y; Zhang H; Zhong Y; Ding X
    Oncotarget; 2016 Aug; 7(34):54317-54328. PubMed ID: 27527871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    McMahon GM; Singh AK
    Curr Opin Nephrol Hypertens; 2019 Nov; 28(6):600-606. PubMed ID: 31567284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
    Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
    Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
    [No Abstract]   [Full Text] [Related]  

  • 17. Endothelial prolyl hydroxylase 2 is necessary for angiotensin II-mediated renal fibrosis and injury.
    Zhao Y; Zeng H; Liu B; He X; Chen JX
    Am J Physiol Renal Physiol; 2020 Aug; 319(2):F345-F357. PubMed ID: 32715763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
    Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
    Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
    Zhang X; Lei Y; Hu T; Wu Y; Li Z; Jiang Z; Yang C; Zhang L; You Q
    J Med Chem; 2020 Sep; 63(17):10045-10060. PubMed ID: 32787144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.